Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Investor Consortium Buys SciClone But Relisting Possible

Executive Summary

Against a background of positive changes to regulations and policies on pharmaceutical marketing in China, US-based SciClone has accepted a buyout offer from a consortium of Chinese investors, but may relist in China in the future.

Advertisement

Related Content

Biopharma Quarterly Deal-Making Statistics, Q2 2017
Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC
China Imposes Tough New Curbs On Rep Sales Activities
China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098950

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel